Intensity Therapeutics Inc (nasdaq:INTS) Share Price

Company Profile

Business description
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
Contact
1 Enterprise Drive
Suite 430
SheltonCT06484-4779
USA
T: +1 203 221-7381
https://www.intensitytherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,061.20	20.50	-0.23%
CAC 40	7,853.59	1.02	-0.01%
DAX 40	23,639.41	35.12	-0.15%
Dow JONES (US)	46,315.27	172.85	0.37%
FTSE 100	9,216.67	11.44	-0.12%
HKSE	26,545.10	0.25	0.00%
NASDAQ	22,631.48	160.75	0.72%
Nikkei 225	45,045.81	257.62	-0.57%
NZX 50 Index	13,231.66	111.63	0.85%
S&P 500	6,664.36	32.40	0.49%
S&P/ASX 200	8,773.50	18.70	-0.21%
SSE Composite Index	3,820.09	11.57	-0.30%